News

On March 21st, GenoScreen will participate in the "International Conference on Tuberculosis" in Brussels.

Deeplex®-MycTB, was used in a study published in The Lancet Infectious Diseases highlighting the spread of tuberculosis strains resistant to first-line antibiotics, not detected by current diagnostic tests.

GenoScreen announced today that it has completed a €1 million fundraising campaign with private investors.

Pioneer company since 2001 in sequencing, genotyping and bioinformatics, GenoScreen provides innovative services and solutions in genomics to address the needs of academic and industrial research teams. At the forefront of genomics in France, GenoScreen develops innovation programs that fuel its technological lead and generate high-performance analytical, products and control services.

pdfDownload the press release245.62 KB

GenoScreen will present the conclusions of the BioDISSPOL project on November 28 at Pollutec Lyon during the panel discussion: "Microbial Biomarkers : Application to the diagnosis and management of polluted sites".

On the 4th and 5th of December 2018, GenoScreen will participate at the 7th edition of the BioFIT business convention which will take place this year in Lille Grand Palais.

Discover Deeplex-MycTB, a next-generation molecular analysis solution that allows, in a single test,

  • to identify the mycobacteria of the M. tuberculosis complex causing tuberculosis,
  • to predict their resistance to multiple antibiotics of first and second intent
  • and to type them for epidemiological surveillance purposes.

Metabiote®, the reference protocol in targeted metagenomics developed by GenoScreen, is now GCLP compliant.

Molecular identification of microorganisms, to strengthen health and food safety.

More information on this page